Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc. in brief
Scribe Therapeutics Inc. is a listed company in the Biotechnology industry, based in Alameda, California, USA. Its market value was $330 M on 30 October 2026, which makes it the 14,382nd largest listed company in the world and the 2,815th largest in the USA on this site. Benjamin L. Oakes is its chief executive. Its shares trade under the symbol SCTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Scribe Therapeutics Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 27 July 2026; shares registered for exchange trading on 21 July 2026.
Events of Scribe Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,788 (Aug 2026) · #2,738 (Oct 2026) · #2,819 (Oct 2026)
Quarterly results
Latest quarter to Sep 2026: revenue $2M (-91.8% on a year earlier), net income $-10M.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 2, 202610-QQuarterly report · period to Jun 2026
- Sep 2, 20268-KCurrent reportResults of operations
- Jul 27, 20268-KCurrent reportBylaws amended
- Jul 27, 2026424B4IPO prospectus
- Jul 20, 2026S-1/AIPO registration (amended)
- Jul 10, 2026S-1/AIPO registration (amended)
- Jul 2, 2026S-1IPO registration
Official filings of Scribe Therapeutics Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $78 M
- Total liabilities
- $101 M
- Total equity
- $-143 M
As of December-2025
Top 63 institutional investors in Scribe Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | a16z Capital Management, L.L.C. | 3,082,725 | New | 16.28% | $57 M | Nov 16, 2026 |
| 2 | Avoro Capital Advisors LLC | 2,598,973 | New | 13.73% | $48 M | Nov 16, 2026 |
| 3 | Ra Capital Management, L.P. | 1,802,178 | New | 9.52% | $33 M | Nov 16, 2026 |
| 4 | Orbimed Advisors LLC | 1,348,825 | New | 7.12% | $25 M | Nov 16, 2026 |
| 5 | Perceptive Advisors LLC | 920,341 | New | 4.86% | $17 M | Nov 16, 2026 |
| 6 | ARK Investment Management LLC | 786,921 | New | 4.16% | $14 M | Nov 13, 2026 |
| 7 | Baker Bros. Advisors LP | 688,691 | New | 3.64% | $13 M | Nov 16, 2026 |
| 8 | Price T Rowe Associates Inc /MD/ | 684,706 | New | 3.62% | $13 M | Nov 16, 2026 |
| 9 | BlackRock, Inc. | 679,786 | New | 3.59% | $13 M | Nov 13, 2026 |
| 10 | Sanofi | 500,000 | New | 2.64% | $9 M | Nov 5, 2026 |
| 11 | Vanguard Capital Management LLC | 407,630 | New | 2.15% | $8 M | Nov 13, 2026 |
| 12 | Franklin Templeton Inc | 380,019 | New | 2.01% | $7 M | Nov 12, 2026 |
| 13 | Farallon Capital Management, L.L.C. | 380,000 | New | 2.01% | $7 M | Nov 16, 2026 |
| 14 | Adage Capital Partners GP, L.L.C. | 380,000 | New | 2.01% | $7 M | Nov 16, 2026 |
| 15 | Geode Capital Management, LLC | 245,412 | New | 1.30% | $5 M | Nov 6, 2026 |
| 16 | State Street Corp | 171,147 | New | 0.90% | $3 M | Nov 12, 2026 |
| 17 | Alyeska Investment Group, L.P. | 150,000 | New | 0.79% | $3 M | Nov 16, 2026 |
| 18 | Menlo Ventures Management, L.P. | 97,690 | New | 0.52% | $2 M | Nov 6, 2026 |
| 19 | TD Asset Management Inc | 83,342 | New | 0.44% | $2 M | Nov 13, 2026 |
| 20 | Sumitomo Mitsui Trust Group, Inc. | 74,910 | New | 0.40% | $1 M | Oct 29, 2026 |
| 21 | Amova Asset Management Americas, Inc. | 74,910 | New | 0.40% | $1 M | Nov 13, 2026 |
| 22 | Northern Trust Corp | 74,721 | New | 0.39% | $1 M | Nov 16, 2026 |
| 23 | UBS Group AG | 71,067 | New | 0.38% | $1 M | Nov 10, 2026 |
| 24 | Vanguard Portfolio Management LLC | 67,039 | New | 0.35% | $1 M | Nov 13, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 64,267 | New | 0.34% | $1 M | Nov 13, 2026 |
Show all 63: investors 26 to 63
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nuveen, LLC | 41,470 | New | 0.22% | $1 M | Nov 10, 2026 |
| 27 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 40,876 | New | 0.22% | $1 M | Nov 13, 2026 |
| 28 | Longaeva Partners L.P. | 34,034 | New | 0.18% | $1 M | Nov 16, 2026 |
| 29 | Charles Schwab Investment Management Inc | 31,644 | New | 0.17% | $1 M | Nov 16, 2026 |
| 30 | Bank Of America Corp /de/ | 27,589 | New | 0.15% | $1 M | Nov 16, 2026 |
| 31 | Point72 Asset Management, L.P. | 22,771 | New | 0.12% | $0 M | Nov 16, 2026 |
| 32 | Wells Fargo & Company/mn | 22,500 | New | 0.12% | $0 M | Nov 16, 2026 |
| 33 | Goldman Sachs Group Inc | 21,635 | New | 0.11% | $0 M | Nov 16, 2026 |
| 34 | Bank of New York Mellon Corp | 20,396 | New | 0.11% | $0 M | Nov 5, 2026 |
| 35 | Focus Partners Wealth | 20,025 | New | 0.11% | $0 M | Nov 12, 2026 |
| 36 | Susquehanna International Group, LLP | 13,641 | New | 0.07% | $0 M | Nov 16, 2026 |
| 37 | Seven Grand Managers, LLC | 10,000 | New | 0.05% | $0 M | Nov 16, 2026 |
| 38 | Rhumbline Advisers | 8,897 | New | 0.05% | $0 M | Nov 10, 2026 |
| 39 | Morgan Stanley | 8,536 | New | 0.05% | $0 M | Nov 13, 2026 |
| 40 | Deutsche Bank AG\ | 8,269 | New | 0.04% | $0 M | Nov 6, 2026 |
| 41 | Jpmorgan Chase & Co | 6,028 | New | 0.03% | $0 M | Nov 12, 2026 |
| 42 | MetLife Investment Management, LLC | 5,814 | New | 0.03% | $0 M | Nov 16, 2026 |
| 43 | Citigroup Inc | 4,742 | New | 0.03% | $0 M | Nov 4, 2026 |
| 44 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 4,636 | New | 0.02% | $0 M | Nov 16, 2026 |
| 45 | Kayne Anderson Rudnick Investment Management LLC | 4,195 | New | 0.02% | $0 M | Nov 13, 2026 |
| 46 | Vanguard Global Advisers, LLC | 3,592 | New | 0.02% | $0 M | Nov 13, 2026 |
| 47 | Tema Etfs LLC | 3,046 | New | 0.02% | $0 M | Oct 16, 2026 |
| 48 | Strs Ohio | 2,600 | New | 0.01% | $0 M | Oct 30, 2026 |
| 49 | BNP Paribas Financial Markets | 2,400 | New | 0.01% | $0 M | Nov 12, 2026 |
| 50 | Police & Firemen's Retirement System of New Jersey | 2,289 | New | 0.01% | $0 M | Nov 9, 2026 |
| 51 | Royal Bank Of Canada | 1,292 | New | 0.01% | $0 M | Nov 16, 2026 |
| 52 | Tower Research Capital LLC (TRC) | 1,024 | New | 0.01% | $0 M | Nov 16, 2026 |
| 53 | Osaic Holdings, Inc. | 1,000 | New | 0.01% | $0 M | Nov 12, 2026 |
| 54 | Steward Partners Investment Advisory, LLC | 1,000 | New | 0.01% | $0 M | Nov 13, 2026 |
| 55 | Ghisallo Capital Management LLC | 1,000 | New | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Legal & General Group Plc | 914 | New | 0.00% | $0 M | Nov 16, 2026 |
| 57 | Ameritas Investment Partners, Inc. | 865 | New | 0.00% | $0 M | Nov 13, 2026 |
| 58 | Russell Investments Group, Ltd. | 730 | New | 0.00% | $0 M | Nov 6, 2026 |
| 59 | Sterling Capital Management LLC | 269 | New | 0.00% | $0 M | Oct 22, 2026 |
| 60 | Allworth Financial LP | 218 | New | 0.00% | $0 M | Nov 17, 2026 |
| 61 | California State Teachers Retirement System | 134 | New | 0.00% | $0 M | Nov 13, 2026 |
| 62 | FMR LLC | 121 | New | 0.00% | $0 M | Nov 10, 2026 |
| 63 | Jacobi Capital Management LLC | 25 | New | 0.00% | $0 M | Nov 5, 2026 |
Mutual funds holding Scribe Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 ARK Genomic Revolution ETFARK Investment Management LLC | 352,097 | $7 M | 1.9% | 0.44% | new | Jul 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 135,567 | $3 M | 0.72% | 0.23% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Scribe Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Avoro Ventures LLCDirector | Buyindirect | +7,905 | $18.25 | $144 K | 3.09 M | Form 4 |
| filed | Orbimed Advisors LLCDirector | Conversionindirect | +348,825 | — | — | 348,825 | Form 4 |
| filed | AH Equity Partners Bio II, L.L.C.10% owner | Conversionindirect | +2.05 M | — | — | 2.05 M | Form 4 |
| filed | Jennifer A. Doudna10% owner | Conversion | +12,511 | — | — | 603,547 | Form 4 |
| filed | Carl L. GordonDirector | Conversionindirect | +348,825 | — | — | 348,825 | Form 4 |
| filed | AH Equity Partners Bio II, L.L.C.10% owner | Conversionindirect | +697,650 | — | — | 697,650 | Form 4 |
| filed | Orbimed Advisors LLCDirector | Buyindirect | +1.00 M | $15.00 | $15.0 M | 1.35 M | Form 4 |
| filed | Carl L. GordonDirector | Buyindirect | +1.00 M | $15.00 | — | 1.35 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Scribe Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $15.00, raising $128.7M · IPO calendar
Fails to deliver
- : 21,515 shares at $17.44
- : 2,173 shares at $17.54
- : 157 shares at $15.60
- : 3,701 shares at $17.96
- : 1,851 shares at $19.30
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Scribe Therapeutics Inc. scorecard#
Passes 0 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 1
- –P/E below its peers' medianNo P/E on file.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- –Earnings yield above the 10-year Treasury yieldNo P/E on file.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- ✗Short-term assets cover short-term liabilities1.0×Current ratio 0.97 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Scribe Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Bylaws or fiscal year changed 1 · Results announced 2
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $100 M | No. 1 | $50 to $250 million | 19 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Scribe Therapeutics Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $147 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Principal ScientistBioinformatics Scientists | 1 | $166 K |
| Scientist IBioinformatics Scientists | 1 | $127 K |
Where: Alameda, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 2 | 2 | $147 K | 2 |
| FY2024 | 6 | 6 | $135 K | 6 |
| FY2023 | 2 | 2 | $125 K | 2 |
| FY2022 | 3 | 3 | $133 K | 3 |
| FY2021 | 1 | 1 | $87 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Scribe Therapeutics Inc.
How Scribe Therapeutics Inc. compares in Biotechnology
- Market cap$330 M · higher than 52% of 726
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Scribe Therapeutics Inc.🇺🇸 | $330 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Scribe Therapeutics Inc.? Verify and update this profile — free
Show Scribe Therapeutics Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.